MedTrace Logo

Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Children Aged 1-12 Years

NCT06614816 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2024-09-26

No results posted yet for this study

Summary

Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Children Aged 1-12 Years: A Phase III, Randomized, Double-Blind, Active-Controlled Study

Conditions

  • Chickenpox Vaccines

Interventions

BIOLOGICAL

Oka strain varicella attenuated live vaccine

lyophilized powder, subcutaneous injection

Sponsors & Collaborators

  • Jiangsu CDC

    collaborator UNKNOWN

  • Southeast University, China

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-10
Primary Completion
2021-07-15
Completion
2022-06-20

Countries

  • China

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06614816 on ClinicalTrials.gov